The use of human embryos for therapeutic or diagnostic purposes which are applied to the human embryo and are useful to it is patentable, but their use for purposes of scientific research is not patentable
Mr Oliver Brüstle is the holder of a patent, filed on 19 December 1997, which concerns isolated and purified neural precursor1 cells produced from human embryonic stem cells used to treat neurological diseases. According to the information supplied by Mr Brüstle, there are already clinical applications, particularly for patients suffering from Parkinson’s disease.
On application by Greenpeace e.V., the Bundespatentgericht (Federal Patent Court, Germany) ruled that
Image via Wikipedia
Misleading advertisements by Swedish company Labo promising hair growth and to remove wrinkles have been pulled. The jury of the self-regulating body for the advertising industry (IAP) ordered the advertisements, which were found in two important Italian newspapers, to be stopped since they were “in violation of article 2 of the self-regulatory code for advertisements”.
According to the group’s conclusions (ruling number 13/09), the statements made in the message, as noted by the IAP Surveillance Committee, “did not overstate, they were misleading”.
This is due to the fact that “they were characterized by a technical and scientific language
Image via Wikipedia
Scientists at the FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology of the European Institute of Oncology in Milan have revealed how to eliminate cancer stem cells, the true reason for cancer’s incurability. Researchers led by Pier Giuseppe Pelicci, Director of the Department of Experimental Oncology of the European Institute of Oncology, and Professor of general pathology at the University of Milan, have discovered how cancer stem cells become immortal.
The same oncogenes that are responsible for triggering the process of tumor formation, also impede stem cells from growing old, and allow them to maintain their
Taxus Cardium Pharmaceuticals Group Inc announced that the Company’s Excellagen flowable dermal matrix in combination with Orbsen Therapeutics’ mesenchymal stromal stem cell therapy Cyndacel-M has been selected for clinical evaluation in a Phase 1b safety study for the potential treaent of chronic diabetic wounds to be funded by the European Union under EU Framework 7.
The project, known by the acronym “REDDSTAR” (Repair of Diabetic Damage by Stromal Cell Administration), is being coordinated by Professor Timothy O’Brien, Dean of Medicine and Director of Ireland’s Regenerative Medicine Institute at National University of Ireland Galway.
In the initial phase of the project, academic